NCT05236803 Better Understand Motor Deficits Associated With Autism Spectrum Disorders: Development of an Assessment Protocol
| NCT ID | NCT05236803 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Charles Perrens, Bordeaux |
| Condition | Autism Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2022-02-07 |
| Primary Completion | 2026-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 110 participants in total. It began in 2022-02-07 with a primary completion date of 2026-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research is a case-control study aiming to characterize motor peculiarities (objective quantitative and qualitative measures) and its psycho-physiological correlates of children with ASD.
Eligibility Criteria
Inclusion Criteria : All participants : * Be between 6 and 11 years old * Mastery of the French language * Be affiliated with a Social Security scheme or benefit from affiliation by a third person * Both parents (or the holder of legal authority) have read, understood and signed the study consent * Be affiliated with social security Participants with ASD should also verify the following inclusion criteria: * Being diagnosed with ASD (DSM-V) Exclusion Criteria : All participants : * Refusal to participate in the research on the part of the participant and / or holders of parental authority. * Be a person benefiting from enhanced protection, namely : persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment. * Have uncorrected visual or hearing problems * To have concomitant psychotropic drug treatments not stabilized, initiated in the last 2 months: antipsychotics, mood stabilizers, anti-epileptics, psychostimulants, antidepressants. * Have a motor handicap of the upper or lower limbs, fitted or not. * Have diagnosed neurological or psychiatric disorders, present a general or metabolic pathology having a known impact on the child's motor skills (eg: Epilepsy, Tics and Gilles de la Tourette Syndrome, Intellectual Deficiency, Neuromuscular Syndrome, Metabolic Neurological Syndrome , neoplasms) * Suspicion of low intellectual efficiency if at least one of the two subtests (Similarities or Matrices) of WISC V (retrieved from the medical file if the TSA participant) presents a result (standard score) strictly lower than 7. Participants without ASD : * Participant with ADHD (Attention Deficit Disorder with or without Hyperactivity) or CDD (Developmental Coordination Disorder)
Contact & Investigator
Anouck AMESTOY, MD
STUDY DIRECTOR
Physician
Frequently Asked Questions
Who can join the NCT05236803 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 11 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05236803 currently recruiting?
Yes, NCT05236803 is actively recruiting participants. Contact the research team at aamestoy@ch-perrens.fr for enrollment information.
Where is the NCT05236803 trial being conducted?
This trial is being conducted at Bordeaux, France, La Rochelle, France, Limoges, France, Poitiers, France.
Who is sponsoring the NCT05236803 clinical trial?
NCT05236803 is sponsored by Centre Hospitalier Charles Perrens, Bordeaux. The principal investigator is Anouck AMESTOY, MD at Physician. The trial plans to enroll 110 participants.